We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
29 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA danicopan 100 mg film-coated tablets, blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA 50 + 100 mg film-coated tablets, composite blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA danicopan 100 mg film-coated tablets, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA 50 + 100 mg film-coated tablets, composite bottle pack.
-
Australian Public Assessment Report (AusPAR)Koselugo (selumetinib sulfate) has been approved for the treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
-
Australian Public Assessment Report (AusPAR)Ultomiris (ravulizumab) has been approved for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder who are anti-aquaporin 4 antibody-positive.
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
Australian Public Assessment Report (AusPAR)AusPAR for Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KOSELUGO selumetinib 10 mg capsule bottle.